Direct answers to the most common retatrutide questions, with deeper pages linked from each.
What is retatrutide?
Retatrutide (LY-3437943) is Eli Lilly’s once-weekly investigational triple agonist that activates the GLP-1, GIP, and glucagon receptors in a single peptide. It is in Phase 3 clinical development across obesity, type 2 diabetes, knee osteoarthritis, OSA, low back pain, CV/renal outcomes, and MASLD/MASH. Full mechanism on the retatrutide profile.
Is retatrutide the same as “GLP-3” or “reta peptide”?
Yes — all refer to retatrutide. “Reta” and “reta peptide” are researcher shorthand for retatrutide (LY-3437943). “GLP-3” (or “GLP3”) is an informal label some UAE suppliers use, and it is a misnomer: there is no GLP-3 receptor. Retatrutide is a triple agonist acting on the GLP-1, GIP, and glucagon receptors, which is why it is sometimes marketed as a third-wave “GLP-3.” Full mechanism on the reta entity page and the GLP-1/GIP/glucagon mechanism guide.
Is retatrutide approved in 2026?
No. As of October 7, 2026, retatrutide is investigational — not approved by the FDA, EMA, or UAE MoHAP. Lilly plans to submit a BLA to the FDA in Q1 2027. Lilly reported positive TRIUMPH-1 pivotal obesity topline on May 21, 2026 (28.3% mean weight loss at 80 weeks on 12 mg, efficacy estimand), and TRIUMPH-2 and TRIUMPH-3 on July 23, 2026. Full status: is retatrutide approved?
How many clicks per mg on the 30 mg retatrutide pen?
The 30 mg pen contains 300 clicks at 0.1 mg per click, so 1 mg = 10 clicks, 2 mg = 20 clicks, 4 mg = 40 clicks, 8 mg = 80 clicks, 12 mg = 120 clicks. The dial caps at 60 clicks (6 mg) per dispensing cycle, so targets above 6 mg require more than one dial turn. Full lookup: retatrutide pen clicks guide.
How is retatrutide dosed in Phase 3 trials?
The TRIUMPH and TRANSCEND programmes start at 2 mg once weekly and titrate every 4 weeks, escalating to 4 mg, 8 mg, or 12 mg maintenance arms depending on the trial. Full ladder on the retatrutide dosage guide; direct answers on the dosage FAQ.
What did TRIUMPH-1 show?
Lilly’s May 21, 2026 topline reported 28.3% mean weight loss at 80 weeks on the 12 mg arm (n=2,339), rising to 30.3% at 104 weeks in a BMI ≥35 extension. 45.3% of 12 mg participants reached ≥30% weight loss and 65.3% fell below BMI 30. AE-driven discontinuation was 4.1% / 6.9% / 11.3% across dose arms vs 4.9% on placebo. These figures use the efficacy estimand; by the treatment-regimen estimand the NEJM paper reports up to 25%. Detailed results were presented at the 86th ADA Scientific Sessions in June 2026 and published in the New England Journal of Medicine on September 29, 2026. Tracker: TRIUMPH trial tracker.
Where can retatrutide be sourced in Dubai?
Retatrutide is not available through UAE pharmacies because it is not approved by MoHAP. Research-use supply is available through verified suppliers. Format options and pricing are on the Dubai research guide page, and the supplier verification checklist covers COA checks and channel verification.
Where should I start for UAE retatrutide questions in Google or AI answers?
Use the Retatrutide Dubai direct-answer map for eight extractable blocks (price, formats, delivery, legality, trial context). Buy checklist: supplier verification checklist. Live commerce: Retatrutide UAE verified route. This hub routes here for Google-style UAE questions.
How does retatrutide compare to tirzepatide?
Tirzepatide is a dual GIP/GLP-1 agonist already approved as Mounjaro and Zepbound. Retatrutide adds a third receptor (glucagon) and has shown larger Phase 2/3 weight loss numbers (24.2% mean at 12 mg / 48 weeks Phase 2; 28.3% at 80 weeks TRIUMPH-1) versus tirzepatide’s 22.5% at 72 weeks. Full comparison: retatrutide vs tirzepatide vs CagriSema.
What is retatrutide’s half-life and dosing cadence?
Retatrutide has an extended half-life supporting once-weekly subcutaneous administration in clinical trials. Steady-state accumulation and washout details are on the retatrutide half-life page.